Article content material continued
Regardless of excessive an infection charges within the second wave of the COVID-19 pandemic, Canadians are nonetheless a great distance from reaching herd immunity, in accordance with a nationwide report.
The report, compiled by the Canadian Blood Providers and Canada’s COVID-19 Immunity Process Drive (CITF), discovered that just one.5 per cent of wholesome Canadians include detected antibodies within the second wave of the pandemic. The result’s based mostly on the evaluation of 33,680 blood samples from blood donor centres throughout Canada — except for Quebec and the Territories — collected throughout October and November final yr.
“Group transmission has been extra intense on this sustained second wave,” Dr. Catherine Hankins, CITF co-chair, said in a launch on Monday. “Nonetheless, even utilizing serology so as to add circumstances to our depend that by no means got here to mild by formal diagnostic assessments, it’s clear that the overwhelming majority of Canadians stay susceptible to COVID-19.”
Made-in-Canada COVID vaccine to be manufactured in Calgary
A COVID-19 vaccine candidate that entered scientific trials final week proposes not solely to be a made-in-Canada resolution to the pandemic, however a made-in-Calgary one.
Windfall Therapeutics, a Canadian biotechnology firm with places of work in Calgary and Toronto, introduced Tuesday it has begun Section I trials of its vaccine. Windfall can be working with one other Calgary firm, Northern RNA, which goals to develop vaccine manufacturing capability on this metropolis.
Windfall Therapeutics was based as a most cancers analysis firm by Calgarian Brad Sorenson, whose younger son was identified with mind most cancers in 2013. As a result of the entire firm’s work was centered on messenger RNA (the identical expertise used within the Pfizer and Moderna COVID vaccines), Windfall was capable of rapidly pivot in 2020 to looking for a vaccine for the novel coronavirus.